Global Antibody and Recombinant Protein CDMO Market Growth (Status and Outlook) 2023-2029
SKU ID : LPI-22402629 | Publishing Date : 24-Jan-2023
Researcher's newest research report, the “Antibody and Recombinant Protein CDMO Industry Forecast” looks at past sales and reviews total world Antibody and Recombinant Protein CDMO sales in 2022, providing a comprehensive analysis by region and market sector of projected Antibody and Recombinant Protein CDMO sales for 2023 through 2029. With Antibody and Recombinant Protein CDMO sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Antibody and Recombinant Protein CDMO industry.
This Insight Report provides a comprehensive analysis of the global Antibody and Recombinant Protein CDMO landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Antibody and Recombinant Protein CDMO portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Antibody and Recombinant Protein CDMO market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Antibody and Recombinant Protein CDMO and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Antibody and Recombinant Protein CDMO.
The global Antibody and Recombinant Protein CDMO market size is projected to grow from US$ million in 2022 to US$ million in 2029; it is expected to grow at a CAGR of % from 2023 to 2029.
United States market for Antibody and Recombinant Protein CDMO is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
China market for Antibody and Recombinant Protein CDMO is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Europe market for Antibody and Recombinant Protein CDMO is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Global key Antibody and Recombinant Protein CDMO players cover Batavia Biosciences, Grifols, Cerbios-Pharma SA, HALIX, Biovian Oy, Catalent, Goodwin Biotechnology, Merck and Hangzhou Hs-biopharm, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2022.
This report presents a comprehensive overview, market shares, and growth opportunities of Antibody and Recombinant Protein CDMO market by product type, application, key players and key regions and countries.
Market Segmentation:
Segmentation by type
Antibody CDMO
Recombinant Protein CDMO
Segmentation by application
Pharmaceutical Company
Biotechnology Company
Generic Company
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Batavia Biosciences
Grifols
Cerbios-Pharma SA
HALIX
Biovian Oy
Catalent
Goodwin Biotechnology
Merck
Hangzhou Hs-biopharm
Wuxibiologics
Bioinnobio
Thousand Oaks Biopharmaceuticals
Cerbios-Pharma SA
Eurogentec
HJB
Bibo Pharma
MabPlex International
Genscriptprobio
Vetter
Etinpro (Beijing) Co
Boehringer Ingelheim BioXcellence
Lonza
3SBio Inc
Porton
This Insight Report provides a comprehensive analysis of the global Antibody and Recombinant Protein CDMO landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Antibody and Recombinant Protein CDMO portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Antibody and Recombinant Protein CDMO market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Antibody and Recombinant Protein CDMO and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Antibody and Recombinant Protein CDMO.
The global Antibody and Recombinant Protein CDMO market size is projected to grow from US$ million in 2022 to US$ million in 2029; it is expected to grow at a CAGR of % from 2023 to 2029.
United States market for Antibody and Recombinant Protein CDMO is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
China market for Antibody and Recombinant Protein CDMO is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Europe market for Antibody and Recombinant Protein CDMO is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Global key Antibody and Recombinant Protein CDMO players cover Batavia Biosciences, Grifols, Cerbios-Pharma SA, HALIX, Biovian Oy, Catalent, Goodwin Biotechnology, Merck and Hangzhou Hs-biopharm, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2022.
This report presents a comprehensive overview, market shares, and growth opportunities of Antibody and Recombinant Protein CDMO market by product type, application, key players and key regions and countries.
Market Segmentation:
Segmentation by type
Antibody CDMO
Recombinant Protein CDMO
Segmentation by application
Pharmaceutical Company
Biotechnology Company
Generic Company
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Batavia Biosciences
Grifols
Cerbios-Pharma SA
HALIX
Biovian Oy
Catalent
Goodwin Biotechnology
Merck
Hangzhou Hs-biopharm
Wuxibiologics
Bioinnobio
Thousand Oaks Biopharmaceuticals
Cerbios-Pharma SA
Eurogentec
HJB
Bibo Pharma
MabPlex International
Genscriptprobio
Vetter
Etinpro (Beijing) Co
Boehringer Ingelheim BioXcellence
Lonza
3SBio Inc
Porton
Frequently Asked Questions
This market study covers the global and regional market with an in-depth analysis of the overall growth prospects in the market. Furthermore, it sheds light on the comprehensive competitive landscape of the global market. The report further offers a dashboard overview of leading companies encompassing their successful marketing strategies, market contribution, recent developments in both historic and present contexts.
- By product type
- By End User/Applications
- By Technology
- By Region
The report provides a detailed evaluation of the market by highlighting information on different aspects which include drivers, restraints, opportunities, and threats. This information can help stakeholders to make appropriate decisions before investing.